American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

MACROGENICS INC (MGNX)

$2.25 -38.02% NASDAQ: MGNX · 15-min delayed

Rockville, Maryland
Public · NASDAQ: MGNX
293 employees

Visit website Follow

$235.2MMarket cap

$149.5MRevenue · FY2025

-$74.6MNet income

293Employees

MGNXNASDAQ

2013IPO

About MACROGENICS INC

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Type: Public · NASDAQ: MGNX
Employees: 293
IPO date: Oct 10, 2013
Headquarters: 9704 MEDICAL CENTER DRIVE
Rockville, Maryland 20850
Phone: 301-251-5172
Industry: Pharmaceuticals
Website: Visit site

Incorporation record

Incorporated in: DE, United States
Registered office: Wilmington, US
Legal entity ID: 5493001KJQUA83L8MH79

Source: GLEIF, the global Legal Entity Identifier registry · checked Jul 26, 2026. A US headquarters does not always mean US incorporation.

Registry IDs

Ticker: MGNX Nasdaq
SEC CIK: 1125345
LEI: 5493001KJQUA83L8MH79
SIC: 2834 PHARMACEUTICAL PREPARATIONS

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show Macrogenics Inc’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/macrogenics-inc/"><img src="https://americancompanies.com/badge/macrogenics-inc.svg" alt="Macrogenics Inc — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow MACROGENICS INC and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $149.5M
Net income: -$74.6M
Total assets: $256.8M
Market cap: $235.2M

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: MGNX

$2.25 -38.02%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$1.33 $4.86

52-week range

Market cap: $235.2M
Shares outstanding: 104.5M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Oct 10, 2013

Macrogenics Inc (MGNX) Stock Price

Reported a net loss of $74.6M in FY2025.
Trading 54% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review MACROGENICS INC.

Write a review

Newsroom

News about MACROGENICS INC

Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year? Zacks Investment Research · 2026-10-09 · positive Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight GlobeNewswire Inc. · 2026-09-08 · positive MacroGenics to Participate in Upcoming Investor Conferences GlobeNewswire Inc. · 2026-02-26 · neutral MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial GlobeNewswire Inc. · 2026-02-23 · negative [Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) GlobeNewswire Inc. · 2026-01-14 · neutral MacroGenics Revenue Doubles in Q2 The Motley Fool · 2025-08-14 · negative

News & sentiment via Polygon.io

FAQ

Macrogenics Inc: frequently asked questions

Is Macrogenics Inc an American company?

Macrogenics Inc is a US-based company headquartered in Rockville, Maryland, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Macrogenics Inc headquartered?

Macrogenics Inc is headquartered in Rockville, Maryland, United States.

Is Macrogenics Inc publicly traded?

Yes — Macrogenics Inc is a publicly traded company. Its stock trades under the ticker symbol MGNX on the NASDAQ.

What does Macrogenics Inc do?

Macrogenics Inc is an American Pharmaceuticals company in the Health & Beauty sector.

Explore